Man Group plc trimmed its position in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 56.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 207,303 shares of the specialty pharmaceutical company’s stock after selling 268,078 shares during the quarter. Man Group plc owned about 0.65% of Paratek Pharmaceuticals worth $2,010,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of PRTK. National Asset Management Inc. bought a new stake in shares of Paratek Pharmaceuticals in the third quarter worth about $117,000. Metropolitan Life Insurance Co. NY increased its holdings in shares of Paratek Pharmaceuticals by 81.4% in the second quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 6,625 shares during the last quarter. MetLife Investment Advisors LLC increased its holdings in shares of Paratek Pharmaceuticals by 57.1% in the second quarter. MetLife Investment Advisors LLC now owns 16,222 shares of the specialty pharmaceutical company’s stock worth $165,000 after purchasing an additional 5,895 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Paratek Pharmaceuticals by 26.8% in the second quarter. Rhumbline Advisers now owns 29,515 shares of the specialty pharmaceutical company’s stock worth $301,000 after purchasing an additional 6,240 shares during the last quarter. Finally, Alps Advisors Inc. increased its holdings in shares of Paratek Pharmaceuticals by 22.5% in the third quarter. Alps Advisors Inc. now owns 56,149 shares of the specialty pharmaceutical company’s stock worth $545,000 after purchasing an additional 10,296 shares during the last quarter. 74.75% of the stock is currently owned by hedge funds and other institutional investors.
In other Paratek Pharmaceuticals news, Director Thomas John Dietz sold 9,330 shares of the business’s stock in a transaction that occurred on Friday, December 21st. The stock was sold at an average price of $5.01, for a total transaction of $46,743.30. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at $37,575. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Evan Loh sold 5,200 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $8.96, for a total value of $46,592.00. Following the transaction, the chief operating officer now owns 294,425 shares of the company’s stock, valued at approximately $2,638,048. The disclosure for this sale can be found here. Insiders have sold 53,248 shares of company stock valued at $377,411 in the last 90 days. Company insiders own 6.20% of the company’s stock.
Several equities research analysts have recently issued reports on PRTK shares. Canaccord Genuity started coverage on Paratek Pharmaceuticals in a report on Wednesday, January 2nd. They issued a “buy” rating and a $14.00 target price on the stock. LADENBURG THALM/SH SH reissued a “buy” rating and set a $18.00 price objective on shares of Paratek Pharmaceuticals in a research note on Tuesday, December 18th. HC Wainwright reduced their price objective on Paratek Pharmaceuticals from $55.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, November 23rd. Guggenheim set a $26.00 price objective on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. Finally, BidaskClub raised Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 6th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $23.44.
Shares of NASDAQ PRTK opened at $6.24 on Friday. The company has a current ratio of 11.39, a quick ratio of 11.39 and a debt-to-equity ratio of 3.97. Paratek Pharmaceuticals Inc has a 1-year low of $4.50 and a 1-year high of $18.40. The company has a market cap of $196.70 million, a price-to-earnings ratio of -1.89 and a beta of 1.19.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.16). Paratek Pharmaceuticals had a negative return on equity of 132.55% and a negative net margin of 2,155.03%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $5.89 million. As a group, analysts predict that Paratek Pharmaceuticals Inc will post -3.51 EPS for the current fiscal year.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.